GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mercury Laboratories Ltd (BOM:538964) » Definitions » Piotroski F-Score

Mercury Laboratories (BOM:538964) Piotroski F-Score : 7 (As of May. 30, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Mercury Laboratories Piotroski F-Score?

Good Sign:

Piotroski F-Score is 7, indicates a very healthy situation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Mercury Laboratories has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.

The historical rank and industry rank for Mercury Laboratories's Piotroski F-Score or its related term are showing as below:

BOM:538964' s Piotroski F-Score Range Over the Past 10 Years
Min: 3   Med: 5   Max: 8
Current: 7

During the past 10 years, the highest Piotroski F-Score of Mercury Laboratories was 8. The lowest was 3. And the median was 5.


Mercury Laboratories Piotroski F-Score Historical Data

The historical data trend for Mercury Laboratories's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mercury Laboratories Piotroski F-Score Chart

Mercury Laboratories Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.00 8.00 7.00 7.00 7.00

Mercury Laboratories Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 7.00 - - -

Competitive Comparison of Mercury Laboratories's Piotroski F-Score

For the Drug Manufacturers - Specialty & Generic subindustry, Mercury Laboratories's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mercury Laboratories's Piotroski F-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Mercury Laboratories's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Mercury Laboratories's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar23) TTM:Last Year (Mar22) TTM:
Net Income was ₹55.8 Mil.
Cash Flow from Operations was ₹24.5 Mil.
Revenue was ₹753.3 Mil.
Gross Profit was ₹449.2 Mil.
Average Total Assets from the begining of this year (Mar22)
to the end of this year (Mar23) was (632.244 + 675.753) / 2 = ₹653.9985 Mil.
Total Assets at the begining of this year (Mar22) was ₹632.2 Mil.
Long-Term Debt & Capital Lease Obligation was ₹24.7 Mil.
Total Current Assets was ₹417.1 Mil.
Total Current Liabilities was ₹164.3 Mil.
Net Income was ₹35.6 Mil.

Revenue was ₹579.2 Mil.
Gross Profit was ₹342.6 Mil.
Average Total Assets from the begining of last year (Mar21)
to the end of last year (Mar22) was (653.708 + 632.244) / 2 = ₹642.976 Mil.
Total Assets at the begining of last year (Mar21) was ₹653.7 Mil.
Long-Term Debt & Capital Lease Obligation was ₹54.9 Mil.
Total Current Assets was ₹360.1 Mil.
Total Current Liabilities was ₹136.3 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Mercury Laboratories's current Net Income (TTM) was 55.8. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Mercury Laboratories's current Cash Flow from Operations (TTM) was 24.5. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar22)
=55.788/632.244
=0.08823809

ROA (Last Year)=Net Income/Total Assets (Mar21)
=35.619/653.708
=0.05448763

Mercury Laboratories's return on assets of this year was 0.08823809. Mercury Laboratories's return on assets of last year was 0.05448763. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Mercury Laboratories's current Net Income (TTM) was 55.8. Mercury Laboratories's current Cash Flow from Operations (TTM) was 24.5. ==> 24.5 <= 55.8 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar22 to Mar23
=24.654/653.9985
=0.03769733

Gearing (Last Year: Mar22)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar21 to Mar22
=54.86/642.976
=0.085322

Mercury Laboratories's gearing of this year was 0.03769733. Mercury Laboratories's gearing of last year was 0.085322. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar23)=Total Current Assets/Total Current Liabilities
=417.087/164.282
=2.53884783

Current Ratio (Last Year: Mar22)=Total Current Assets/Total Current Liabilities
=360.109/136.317
=2.6417028

Mercury Laboratories's current ratio of this year was 2.53884783. Mercury Laboratories's current ratio of last year was 2.6417028. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Mercury Laboratories's number of shares in issue this year was 1.2. Mercury Laboratories's number of shares in issue last year was 1.2. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=449.177/753.337
=0.59624975

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=342.643/579.238
=0.59154096

Mercury Laboratories's gross margin of this year was 0.59624975. Mercury Laboratories's gross margin of last year was 0.59154096. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar22)
=753.337/632.244
=1.1915289

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar21)
=579.238/653.708
=0.88608064

Mercury Laboratories's asset turnover of this year was 1.1915289. Mercury Laboratories's asset turnover of last year was 0.88608064. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+1+0+1+0+1+1+1
=7

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Mercury Laboratories has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.

Mercury Laboratories  (BOM:538964) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Mercury Laboratories Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Mercury Laboratories's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Mercury Laboratories (BOM:538964) Business Description

Traded in Other Exchanges
N/A
Address
Gorwa Road, 2/13-14, Gorwa Industrial estate, P.B. No. 3001, Vadodara, GJ, IND, 390016
Mercury Laboratories Ltd is an India-based pharmaceutical company. It is engaged in the manufacturing and distribution of pharmaceutical drugs, herbs, and laboratory and surgical materials. The group produces medicines and formulations in the segments of pediatrics, obstetrics, gynecology, surgeon segment, multivitamin and nutrition supplements, antibiotics, and others. The company sells its products in India and internationally, of which key revenue is derived from sales made in India.

Mercury Laboratories (BOM:538964) Headlines

No Headlines